Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of intraoperative subanesthetic-dose esketamine on postoperative depressive symptoms in breast cancer patients
ChiCTR2600117573Phase 4Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in major depressive disorder (MDD), anxiety disorder, pain and 1 more (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Incidence of depressive symptoms at 1 month postoperatively. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)anxiety disorderpainPersistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on ChiCTR2600117573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117573.